Albemarle Corporation

LSE:0HC7 Stock Report

Market Cap: US$9.8b

Albemarle Valuation

Is 0HC7 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0HC7 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$126.98
Fair Value
34.8% undervalued intrinsic discount
27
Number of Analysts

Below Fair Value: 0HC7 ($82.76) is trading below our estimate of fair value ($126.98)

Significantly Below Fair Value: 0HC7 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0HC7?

Key metric: As 0HC7 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0HC7. This is calculated by dividing 0HC7's market cap by their current revenue.
What is 0HC7's PS Ratio?
PS Ratio1.8x
SalesUS$5.38b
Market CapUS$9.83b

Price to Sales Ratio vs Peers

How does 0HC7's PS Ratio compare to its peers?

The above table shows the PS ratio for 0HC7 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.8x
CRDA Croda International
2.7x5.5%UK£4.5b
JMAT Johnson Matthey
0.2x-31.5%UK£2.5b
ELM Elementis
1.6x3.2%UK£925.5m
VCT Victrex
2.8x4.8%UK£852.2m
0HC7 Albemarle
1.8x10.4%US$9.8b

Price-To-Sales vs Peers: 0HC7 is good value based on its Price-To-Sales Ratio (1.8x) compared to the peer average (1.8x).

Price to Sales Ratio vs Industry

How does 0HC7's PS Ratio compare vs other companies in the GB Chemicals Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
JMAT Johnson Matthey
0.2x-31.5%US$3.09b
SYNT Synthomer
0.1x3.4%US$282.00m
CAR Carclo
0.1x9.7%US$19.49m
HEIQ HeiQ
0.2xn/aUS$9.61m
0HC7 1.8xIndustry Avg. 1.1xNo. of Companies7PS01.22.43.64.86+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0HC7 is expensive based on its Price-To-Sales Ratio (1.8x) compared to the UK Chemicals industry average (1.1x).

Price to Sales Ratio vs Fair Ratio

What is 0HC7's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0HC7 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.8x
Fair PS Ratio0.9x

Price-To-Sales vs Fair Ratio: 0HC7 is expensive based on its Price-To-Sales Ratio (1.8x) compared to the estimated Fair Price-To-Sales Ratio (0.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0HC7 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$83.50
US$102.24
+22.4%
30.7%US$225.00US$68.00n/a27
Feb ’26US$83.83
US$115.20
+37.4%
28.2%US$225.00US$73.00n/a27
Jan ’26US$85.74
US$117.72
+37.3%
28.4%US$225.00US$73.00n/a26
Dec ’25US$107.70
US$116.41
+8.1%
29.3%US$225.00US$73.00n/a26
Nov ’25US$98.87
US$113.68
+15.0%
31.2%US$225.00US$73.00n/a26
Oct ’25US$94.20
US$111.98
+18.9%
32.4%US$225.00US$73.00n/a26
Sep ’25US$90.10
US$112.29
+24.6%
32.3%US$225.00US$73.00n/a26
Aug ’25US$93.91
US$126.80
+35.0%
27.0%US$225.00US$81.00n/a25
Jul ’25US$96.39
US$148.46
+54.0%
24.9%US$275.00US$81.00n/a24
Jun ’25US$122.17
US$153.44
+25.6%
24.3%US$275.00US$81.00n/a25
May ’25US$118.64
US$152.40
+28.5%
24.1%US$275.00US$81.00n/a27
Apr ’25US$131.12
US$150.03
+14.4%
25.1%US$275.00US$81.00n/a27
Mar ’25US$142.93
US$152.36
+6.6%
26.6%US$300.00US$90.00n/a27
Feb ’25US$117.27
US$162.37
+38.5%
25.2%US$300.00US$90.00US$83.8327
Jan ’25US$144.79
US$188.34
+30.1%
30.3%US$308.00US$90.00US$85.7427
Dec ’24US$124.41
US$190.80
+53.4%
30.2%US$308.00US$90.00US$107.7027
Nov ’24US$122.21
US$238.29
+95.0%
23.5%US$350.00US$155.00US$98.8726
Oct ’24US$170.99
US$264.67
+54.8%
17.8%US$350.00US$155.00US$94.2024
Sep ’24US$200.73
US$264.69
+31.9%
18.3%US$350.00US$155.00US$90.1025
Aug ’24US$208.29
US$267.48
+28.4%
19.9%US$360.00US$155.00US$93.9125
Jul ’24US$222.57
US$263.19
+18.2%
20.6%US$360.00US$155.00US$96.3925
Jun ’24US$195.78
US$264.95
+35.3%
21.9%US$360.00US$155.00US$122.1724
May ’24US$184.62
US$285.85
+54.8%
25.2%US$498.00US$155.00US$118.6422
Apr ’24US$220.89
US$319.21
+44.5%
19.6%US$498.00US$155.00US$131.1222
Mar ’24US$252.85
US$315.70
+24.9%
19.3%US$498.00US$155.00US$142.9324
Feb ’24US$282.87
US$313.10
+10.7%
19.8%US$497.00US$155.00US$117.2723
Analyst Price Target
Consensus Narrative from 27 Analysts
US$101.23
Fair Value
18.2% undervalued intrinsic discount
27
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/19 21:08
End of Day Share Price 2025/02/19 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Albemarle Corporation is covered by 45 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
William SeleskyArgus Research Company
Benjamin KalloBaird
Ishan MajumdarBaptista Research